Bone remodeling, comprising resorption of existing bone and de novo bone formation, is required for the maintenance of a constant bone mass. Prostaglandin (PG)E 2 promotes both bone resorption and bone formation. By infusing PGE 2 to mice lacking each of four PGE receptor (EP) subtypes, we have identified EP4 as the receptor that mediates bone formation in response to this agent. Consistently, bone formation was induced in wild-type mice by infusion of an EP4-selective agonist and not agonists specific for other EP subtypes. In culture of bone marrow cells from wild-type mice, PGE2 induced expression of core-binding factor ␣1 (Runx2͞Cbfa1) and enhanced formation of mineralized nodules, both of which were absent in the culture of cells from EP4-deficient mice. Furthermore, administration of the EP4 agonist restored bone mass and strength normally lost in rats subjected to ovariectomy or immobilization. Histomorphometric analysis revealed that the EP4 agonist induced significant increases in the volume of cancellous bone, osteoid formation, and the number of osteoblasts in the affected bone of immobilized rats, indicating that activation of EP4 induces de novo bone formation. In addition, osteoclasts were found on the increased bone surface at a density comparable to that found in the bone of control animals. These results suggest that activation of EP4 induces bone remodeling in vivo and that EP4-selective drugs may be beneficial in humans with osteoporosis. B ones undergo continuous remodeling through repeated cycles of destruction and rebuilding (1). This remodeling is mediated by the well balanced actions of osteoclasts, which resorb old bones, and osteoblasts, which form new bones. However, in the elderly, especially in postmenopausal women, the extent of bone resorption far exceeds that of bone rebuilding, resulting in osteoporosis and the associated increases in bone fragility and susceptibility to fractures (2). About 100 million people are estimated to suffer from this debilitating disease worldwide. Several drugs have been developed to treat osteoporosis, with most inhibiting bone resorption and only a few promoting bone formation (3). Such modulation of only one of the two processes in bone remodeling renders these drugs of limited efficacy in restoring the normal balance and bone mass.
B
ones undergo continuous remodeling through repeated cycles of destruction and rebuilding (1) . This remodeling is mediated by the well balanced actions of osteoclasts, which resorb old bones, and osteoblasts, which form new bones. However, in the elderly, especially in postmenopausal women, the extent of bone resorption far exceeds that of bone rebuilding, resulting in osteoporosis and the associated increases in bone fragility and susceptibility to fractures (2) . About 100 million people are estimated to suffer from this debilitating disease worldwide. Several drugs have been developed to treat osteoporosis, with most inhibiting bone resorption and only a few promoting bone formation (3) . Such modulation of only one of the two processes in bone remodeling renders these drugs of limited efficacy in restoring the normal balance and bone mass.
Recently, significant advances have been made in our understanding of molecular mechanisms of osteoclast and osteoblast differentiation (4) , but such knowledge has not been exploited fully to develop a drug that corrects the imbalance and restores normal bone remodeling. Prostaglandins (PGs) are a group of lipid mediators that are produced from arachidonic acid in a variety of tissues under various physiological and pathophysiological conditions and serve to maintain local homeostasis (5) . Among them, PGs of the E type work bimodally in bone metabolism (6) . PGE 2 potently induces bone resorption in bone organ cultures, whereas repeated injection of this compound in vivo induces bone formation in a variety of animals including humans. However, the use of PGE 2 as a therapeutic agent in the treatment of bone loss has been hindered by unwanted actions that systemically applied PGE 2 exerts in the body. It is not understood, either, the mechanism by which it induces bone formation or how this in vivo effect is related to its bone resorbing activity in vitro.
PGE 2 exerts its effects through interaction with specific cell surface receptors (5) . Four subtypes of PGE receptors-EP1, EP2, EP3, and EP4-have been identified. These receptors are encoded by distinct genes and are expressed differentially in the body. With the use of homologous recombination, we have generated mice that lack each of the four EP subtypes individually (7) (8) (9) . We also have screened compounds on a panel of the cloned receptors and developed drugs that act specifically at each EP subtype (10) . With these tools, we now have investigated which EP subtype mediates the bone-forming activity of PGE 2 and how activation of this receptor induces bone formation. We have also used ovariectomized or immobilized rats as models of diseases with bone loss and examined the efficacy of EP-subtypespecific drugs in the treatment of this condition.
Materials and Methods
Mice. Mice deficient in each EP subtype (7-9) were backcrossed for more than five generations into C57BL͞6CrSlc (Japan SLC, Hamamatsu, Japan). Males of the F2 progenies of N10 EP1 Ϫ͞Ϫ mice, N5 EP2 Ϫ͞Ϫ mice, and N5 EP3 Ϫ͞Ϫ mice were used. Because EP4 Ϫ͞Ϫ mice do not survive in the C57BL͞6 background because of patent ductus arteriosus (8) , survivors of F2 progenies in the mixed genetic background of 129͞Ola ϫ C57BL͞6 were intercrossed and the resulting male survivors were used. Mice were treated according to the guidelines for the protection of experimental animals of Kyoto University and Ono Pharmaceutical. 0.7, 56, and 620 nM for radioligand binding to EP4, EP3, and EP2, respectively, and values of more than 10 M for EP1 and receptors for PGD 2 , PGF 2 ␣, PGI 2 , or thromboxane A 2 . This compound was administered as an inclusion complex with ␣-cyclodextrin.
Local Infusion of PGE2 and EP Agonists. Eight-week-old mice with body weights of 22-25 g were anesthetized. Their right femora were exposed, and the periosteum was removed around their shaft 8 mm in length. A polyvinyl catheter was fixed distally to the exposed bone surface and was connected proximally to an Alzet 1002 miniosmotic pump (Alza) implanted s.c. in the back and containing PGE 2 or EP agonists in ethanol͞propylene glycol (40:60, vol͞vol). The infusion was performed at a rate of 0.25 l͞hr for 6 weeks, with reservoir replacement every other week. The mice then were killed. Soft x-rays of the femur were taken as described (11) . The anteroposterior and lateral diameters of the femur were measured in a callus-containing region of the treated bone and in the corresponding region of the contralateral femur. Each bone volume was calculated assuming the horizontal section of the femur to be elliptical, and the volume of the callus was obtained by subtraction. Histology of the femur was analyzed as described (12) .
Bone Marrow Cell Culture. Bone marrow cells were obtained from femora of 8-week-old mice and cultured in the medium containing PGE 2 or vehicle as described (13) . The medium was replaced every 3 days. After 21 days, the cells were rinsed with PBS, fixed in a 1:1:1.5 solution of 10% formalin͞methanol͞water for 2 h, and stained with the von Kossa method for mineralization. Nuclei were counterstained with neutral red. Photographs were taken with transmitted light, and the black-stained area of the mineralized nodules was measured with NIH IMAGE.
Immunoblot was performed as described with 100 g protein of cell lysates and antibodies to core-binding factor ␣1 (Cbfa1) (14) . Bound antibodies were detected with ECL Plus reagents (Amersham Pharmacia). Northern blot analysis was performed with 0.6 g of poly(A) RNA. Hybridization was performed with random-primed 32 P-labeled probes prepared, with the 0.8-kb EcoRI-HindIII fragment of mouse Cbfa1 cDNA as a template (15) .
Administration of ONO-4819 to Ovariectomized Rats. Fifteen-weekold female Crj:CD(SD)IGS (IGS) rats were anesthetized, and both ovaries were removed. ONO-4819 was dissolved in saline and administered either by i.v. infusion through a catheter into the right jugular vein or by s.c. injection in the back. Infusion was performed at a rate of 4 ml͞kg per hr for 2 h twice per day. Seventy days after surgery, rats were killed and both femora and the fourth lumbar body were isolated. The right femur was fixed in 10% formalin and subjected to analysis with Micro Focus X-ray-Computed Tomography (MCT-CB100MF; Hitachi, Tokyo). The density of cancellous bone was measured in the left femur in a 0.77-mm-thick slice at a distance of 3 mm from the epiphysial growth plate by peripheral quantitative-computed tomography (Stratec Medizintechnik, Pforzeim, Germany) with a voxel size of 0.12 mm at a tube voltage of 50 kV. The lumbar body was used for compression testing, which was performed with a bone compression machine (MZ-500D; Maruto, Tokyo).
Immobilized Rat Model and Histomorphometric Analysis of Bone
Tissues. Five-to six-week-old male IGS rats were anesthetized, and the left sciatic and femoral nerves each were resected at a length of 10 mm. Sham-operated rats received a similar operation without nerve resection. The rats then were systematically infused i.v. either with vehicle or ONO-4819 for 2 h twice a day. For bone density measurement, the rats were killed after 14 days, and the density of trabeculae of the left tibia was examined 4 mm from the proximal end as described above. For histomorphometric analysis, the infusion of ONO-4819 at 100 ng͞kg per min or vehicle for 2 h twice a day continued for 28 days. On days 24 and 27, the rats received injection with tetracycline and calcein, respectively. After sacrifice on day 29, the left tibia was isolated. The sagittal block of the metaphysis was obtained, incubated with the Villanueva bone stain for 7 days, dehydrated, and embedded in methylmethacrylate. Sections of 4-m thickness were prepared and subjected to the analysis by using a microscope coupled to the computerized bone morphometry analysis system (Luzex F Bone system, NIRECO, Tokyo). The primary parameters were measured as recommended (16) in an area between 1 and 1.2 mm from the growth plate and 200 m apart from the cortical bone and were used to calculate the secondary parameters shown in Table 1 .
Statistical Analysis. Data are presented as mean Ϯ SE and were analyzed by using either Student's t test or, after variation analysis, Welch's t test or the Dunnett multiple comparison test. An associated probability (P value) of Ͻ0.05 was considered significant.
Results
Lack of PGE2-Induced Bone Formation in EP4 ؊͞؊ Mice. By using a miniosmotic pump, we continuously infused PGE 2 into the periosteal region of the femur of wild-type C57BL͞6 mice or mice deficient in each EP subtype. After 6 weeks, the femur was isolated and bone formation was examined by both radiographic and histological analyses. Radiography revealed that PGE 2 induced extensive callus formation on the femur at the site of infusion in wild-type mice (Fig. 1a) . The extent of callus formation depended on the dose of PGE 2 between 0.8 and 800 nmol͞kg per day (Fig. 1b) . Histological analysis showed marked thickening of the femoral cortex, with a large amount of woven bone as well as substantial accumulation of cells and bone matrix (Fig. 1a) . Little bone formation was evident in the wild-type mice infused with vehicle alone. When PGE 2 was infused to mice deficient in each EP receptor subtype, the callus formation of as much extent as that seen in wild-type mice was observed in the cortex of the femora of EP1 Ϫ͞Ϫ , EP2 
PGE2 Induces Osteoblast Differentiation in Vitro Through EP4 Receptor
Activation. The bone-forming activity of PGE 2 can be evaluated in vitro in a primary culture of rat bone marrow cells by measuring the formation of mineralized nodules (13) . By application of this system to mice, we examined the mechanism of EP4-induced bone formation. Bone marrow cells were harvested from either wild-type C57BL͞6 mice or EP4 Ϫ͞Ϫ mice and were cultured with PGE 2 for 3 weeks. Mineralized nodules were stained black by the von Kossa method, and their areas were summed. Culture of wild-type cells with vehicle alone resulted in the formation of mineralized nodules, and this was enhanced by the addition of PGE 2 in a concentration-dependent manner (Fig.  2a) . In contrast, neither the basal level of mineralization nor its enhancement by PGE 2 was detected in cell culture derived from EP4 Ϫ͞Ϫ mice. These results suggested that PGE 2 might promote osteoblast differentiation from precursor bone marrow cells. To test this possibility, we examined the effect of PGE 2 on the expression of Cbfa1 in these cells. Cbfa1 is an osteoblast-specific transcription factor and an important determinant of osteoblast differentiation (4, 17) . Immunoblot analysis with mouse mAb ␣A8G5 to Cbfa1 (14) detected two bands of Ϸ65 kDa in lysates prepared from vehicle-treated, wild-type cells on day 4 or 7 ( Fig.  2b) . The amounts of these proteins were markedly increased, and the duration of their expression was prolonged in cells cultured with 100 nM PGE 2 . In contrast, only a very little amount of Cbfa1 was detected in vehicle-treated EP4 Ϫ͞Ϫ cells, and the abundance was not enhanced by the addition of PGE 2 . These results suggest that PGE 2 increases the amount of Cbfa1 via EP4. This effect of PGE 2 appears to be exerted at the mRNA level, given that Northern blot analysis revealed that culture of wild-type cells with PGE 2 increased the level of Cbfa1 mRNA (Fig. 2c) . Immunostaining of wild-type cultures with anti-Cbfa1 antibody revealed that incubation with PGE 2 induced a significant increase in the number of cells containing Cbfa1 immunoreactivity (Fig. 2d) , indicating that PGE 2 increased the number of Cbfa1-expressing cells and not simply increased the amount of Cbfa1 in a fixed number of cells. These results taken together identify EP4 as the EP receptor subtype that mediates the bone-forming activity of PGE 2 , and suggest that EP4 achieves this effect through induction of osteoblast differentiation.
An EP4-Selective Agonist Potently Stimulates Bone Formation in Vivo.
To corroborate these observations pharmacologically, we next applied agonists DI-004, AE1-259, AE-248, and AE1-329, which specifically target EP1, EP2, EP3, and EP4, respectively (10). Wild-type mice were infused continuously with one of these compounds for 6 weeks, and their in vivo bone-forming activities were assessed. Infusion of the selective EP4 agonist, AE1-329, markedly increased bone formation, as detected both radiographically and histologically, in a dose-dependent manner (Fig.  3 a and b) . In contrast, the femora of mice infused with each of the agonists specific for the other three EP subtypes did not appear to differ from those of animals infused with vehicle ( Fig.  3 c-e) . We also tested the in vitro activities of these agonists on the formation of mineralized nodules in primary cultures of bone marrow cells. AE1-329 again was the only one of four compounds capable of inducing mineralized nodule formation (data not shown).
Administration of an EP4 Agonist Prevents Bone Loss and Restores Bone Mass and Strength in Rats Subjected to Ovariectomy and
Immobilization. Given that the EP4 agonist is a potent inducer of bone formation in healthy animals, we next investigated whether this type of drugs might exert a similar action in animals with bone loss and, thereby, restore bone mass and strength. To this end, we modified AE1-329 to increase its chemical stability (Fig.  4a) . The resulting compound, ONO-4819, was administered to ovariectomized (OVX) rats, a model for human postmenopausal osteoporosis. Both ovaries were removed from 15-week-old female rats, and the effect of daily administration of ONO-4819 was examined. Seventy days after ovariectomy, vehicle-treated control OVX rats exhibited marked osteoporosis, as was apparent from the almost complete loss of bone trabeculae (Fig. 4b) . s.c. injection of ONO-4819 three times per day beginning on the day of ovariectomy inhibited bone loss in a dose-dependent manner (Fig. 4 b and c) ; at a dose of 10 g͞kg, the drug completely prevented the bone loss. Importantly, the full restoration of bone density also was obtained when the injection was initiated 20 days after ovariectomy. We next evaluated the effect of the EP4 agonist on bone strength by subjecting the fourth lumbar body from these animals to the compression test. Ovariectomy resulted in a marked reduction in bone strength. This fragility was prevented by treatment of animals with ONO-4819 (Fig. 4d) . In animals injected with ONO-4819 at 30 g͞kg three times per day or infused at 100 ng͞kg per min for 2 h twice per day, bone strength was significantly greater than that in vehicletreated OVX rats. Histology of bones revealed that trabeculae similar in architecture and appearance to those found in the sham-operated rats and lined with osteoblasts were formed in the OVX rats treated with ONO-4819 (Fig. 4e) .
In healthy animals, bone remodeling is stimulated by the mechanical tension applied to each bone as a result of its daily use, and prolonged immobilization results in a reduction in bone mass and deterioration of bone architecture. We therefore examined the effect of ONO-4819 on bone loss of immobilized rats. Immobilization of a hind limb induced a significant reduction in bone density of the tibia of the affected leg in 2 weeks. The infusion of ONO-4819 inhibited this reduction in a dosedependent manner, preventing it completely at higher doses tested (Fig. 5) . We next used rats subjected to this model and performed histomorphometric analysis on the effects of the ONO-4819 treatment (Table 1) . Because the immobilization in our model affected significantly the cancellous bone and not the cortical bone, we limited our description to the changes in the cancellous bone of the metaphysis. This analysis revealed significant reduction in the volume of cancellous bone in immobilized rats as determined by bone volume (BV͞TV). The ONO-4819 infusion significantly increased the bone volume including the osteoid volume and completely restored it in the immobilized animals. This was reflected by the significant increase in bone formation rate in the ONO-4819-treated animals. The significant increases in bone surface (BS͞TV) and in the bone surface lined with osteoblasts (Ob.S͞BS) were also noted. These findings together with a similar density of osteoclasts on bone surface (N.Oc͞BS) in ONO-4819-treated rats indicate that the total number of osteoclasts in the tissue markedly increased with the increase in the bone surface. On the other hand, the calcification rate as determined by double fluorescence labeling (mineral apposition rate) was not affected by this treatment.
In the above experiments, ONO-4819 administration caused no significant change in the serum concentrations of alkaline phosphatase, calcium, and inorganic phosphate in the animals (data not shown). Ectopic calcification in tissues such as cardiac valves or aorta was not found. No significant change in the blood pressure was detected in conscious rats by either infusion or injection of the drug at the doses described, although the infusion of the highest dose (100 ng͞kg per min i.v.) induced less than 20% elevation of the heart rate.
Discussion
In this study, with both genetic and pharmacological approaches, we have unambiguously identified EP4 as the receptor that mediates the bone-forming activity of PGE 2 . The role of this receptor in bone formation was suggested previously only indirectly by the use of a limited repertory of EP-acting compounds (18) . We have found that activation of EP4 induced callus formation on the femur of mice and restored the volume of cancellous bone in OVX or immobilized rats. The histomorphometric analysis in the latter model revealed increases in both the total volume of the bone and the volume of osteoid, suggesting that these effects of the EP4 activation are exerted by de novo bone formation. In vitro in the bone marrow cell culture, EP4 activation increased the number of Cbfa-1-positive cells, suggesting that EP4 exerts such an effect by inducing osteoblast differentiation. Consistently, the density of osteoblasts lining the bone surface (Ob.S͞BS) increased with ONO-4819 treatment in the in vivo models. It is noteworthy that the callus induced by PGE2 in mice contained many fibrous tissues and that the bone of ONO-4819-treated rats showed a mineralizing surface (MS͞ OS) of about half of that seen in sham-operated animals. These results indicate that the osteoblasts induced by EP4 activation produce bone matrix at a rate exceeding that of calcification. This was reflected by the prolonged mineralization lag time (Mlt) with an unchanged mineral apposition rate. However, the trabeculae formed were well connected, and the majority was sufficiently calcified as shown in Fig. 4e and Table 1 , yielding substantial strength to the bone of OVX animals (Fig. 4d) .
Our current study thus suggests that EP4 activation induces osteoblasts and thereby stimulates de novo bone formation. Previously, we also noted in bone organ culture that EP4 in mature osteoblasts mediates PGE 2 -induced osteoclast differentiation (19, 20) . We wondered how these two EP4 actions are coordinated in vivo in the bone of animals treated with the EP4 agonist. The bone morphometric analysis has shown that the EP4 agonist did not decrease the density of osteoclasts despite the increase in the bone surface, suggesting that it increased the number of osteoclasts in parallel with the de novo increase in bone. It is tempting to speculate that the PGE 2 -EP4 signaling first works in osteoblast precursors to induce osteoblasts for bone formation and then works in mature osteoblasts for induction of osteoclasts on newly formed bones. Both EP4 and EP2 respond to PGE 2 and are coupled to activation of adenylate cyclase. Both also are implicated in PGE 2 -induced osteoclastogenesis (19) (20) (21) . It is interesting in this respect that we have not observed any involvement of EP2 in PGE 2 -induced bone formation in mice (Figs. 1 and 3) . We neither have observed any bone-forming effects of the EP2-selective agonist in OVX rats (data not shown). Although we cannot exclude a redundant role of EP2 in other species, these results indicate that EP4 is the only system mediating PGE 2 -induced bone formation at least in rodents. It is curious, therefore, that the skeleton of EP4 Ϫ͞Ϫ mice either alive to adulthood or dead in the neonatal period is apparently normal (19, 20) , suggesting that some pathway(s) other than the PGE 2 system works for physiological maintenance of bone. It remains to be clarified in what physiological or pathological context the PGE 2 -EP4 signaling is mobilized for bone formation.
Several types of drugs currently are used for the treatment of bone loss (3). These drugs either inhibit differentiation and functions of osteoclasts or activate osteoblasts. However, none of these drugs are able to restore the balance between bone formation by osteoblasts and bone resorption by osteoclasts. PGE 2 -EP4 appears to induce both osteoblastogenesis and osteoclastogenesis and to integrate the two actions temporarily and spatially in situ in bone remodeling. In this respect, the action of PGE 2 may be similar to that of PTH, which also promotes both bone formation and resorption (1, 3, 22) . Recently, clinical efficacy of PTH for postmenopausal osteoporosis has been reported (23) . On the other hand, the numerous, unwanted effects of PGE 2 injected systematically have precluded its use in therapeutics for bone loss. Because EP4 agonists are selective to only one subtype of EP receptors, they are expected to avoid several adverse actions caused by systemic administration of PGE 2 . Indeed, ONO-4819 lacks the uterine-contracting activity of PGE 2 . Furthermore, administration of ONO-4819 in rodents does induce diarrhea, hypotension, and thickening of intestinal epithelium but at higher doses than that required for bone formation. However, given various differences between the rodent models and human patients, it may be too early to conclude that EP4 agonists exert beneficial effects in humans.
Their therapeutic potential will be tested rigorously in future studies.
